Adage Capital Partners’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Adage Capital Partners’s Portfolio VIRX Stock Details VIRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-300,000	Closed	-$477K	–	949
2023 Q1	$477K	Hold	300,000	–	–	﹤0.01%	818
2022 Q4	$438K	Hold	300,000	–	–	﹤0.01%	862
2022 Q3	$1.28M	Sell	300,000 -170,000	-36%	-$720K	﹤0.01%	880
2022 Q2	$1.82M	Buy	470,000 +216,309	+85%	+$616K	﹤0.01%	887
2022 Q1	$1.21M	Buy	+253,691	New	+$764K	﹤0.01%	928
2018 Q4	–	Sell	-2,857	Closed	-$200K	–	767
2018 Q3	$200K	Hold	2,857	–	–	﹤0.01%	706
2018 Q2	$212K	Hold	2,857	–	–	﹤0.01%	725
2018 Q1	$272K	Buy	+2,857	New	+$490K	﹤0.01%	711
2015 Q1	–	Sell	-3,706	Closed	-$1.99M	–	761
2014 Q4	$1.99M	Buy	+3,706	New	+$1.67M	﹤0.01%	671
2014 Q1	–	Sell	-179	Closed	-$178K	–	743
2013 Q4	$178K	Buy	+179	New	+$185K	﹤0.01%	673
2013 Q3	–	Sell	-714	Closed	-$778K	–	749
2013 Q2	$778K	Buy	+714	New	+$796K	﹤0.01%	666

Other funds holding VIRX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Adage Capital Partners's VIRX Position: Q2 2023 in Review

Adage Capital Partners sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q2 2023, closing a stake of 300,000 shares — an estimated $477K sold.

Adage Capital Partners first reported a position in VIRX in Q2 2013 and held it in 11 quarters. The position peaked at $1.99M in Q4 2014. 41 funds tracked by Wall St. Rank hold VIRX as of Q2 2023.

Adage Capital Partners reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Adage Capital Partners sold 300,000 Viracta Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $477K.
Adage Capital Partners first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2013 and held it in 11 quarters.
Adage Capital Partners's Viracta Therapeutics, Inc. Common Stock position peaked at $1.99M in Q4 2014.
41 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Adage Capital Partners's 13F filing for Q2 2023, filed 14 Aug 2023.